ADIM
GTHX

Alpha DNA Investment Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Alpha DNA Investment Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-42,477
Closed -$530K – 211
2022
Q3 		$530K Buy
+42,477
New +$485K 0.44% 119

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Alpha DNA Investment Management's GTHX Position: Q4 2022 in Review

Alpha DNA Investment Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2022, closing a stake of 42,477 shares — an estimated $530K sold.

Alpha DNA Investment Management first reported a position in GTHX in Q3 2022 and held it in 1 quarter. The position peaked at $530K in Q3 2022. 116 funds tracked by Wall St. Rank hold GTHX as of Q4 2022.

  • Alpha DNA Investment Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Alpha DNA Investment Management sold 42,477 G1 Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $530K.
  • Alpha DNA Investment Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Alpha DNA Investment Management's G1 Therapeutics, Inc. Common Stock position peaked at $530K in Q3 2022.
  • 116 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Alpha DNA Investment Management's 13F filing for Q4 2022, filed 27 Jan 2023.